---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-26-012751"
form_type: "8-K"
ticker: "MNPR"
cik: "0001645469"
company_name: "Monopar Therapeutics"
filed_at: "2026-04-20T23:59:59+00:00"
generated_at: "2026-05-15T05:20:01.950631+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Monopar Phase 3 ALXN1840 data shows greater neurologic benefit vs SoC in Wilson disease

## Summary
- Neurologic worsening at Week 48: 9% ALXN1840 vs 25% SoC (p=0.038); improvement 45% vs 32%.
- CGI-S improvement from baseline to Week 48: 61% ALXN1840 vs 17% SoC (p=0.008); CGI-I 47% vs 19% (p=0.003).
- Durable neurologic benefit over ~3 years in long-term follow-up; consistent across treatment-naïve and experienced.
- Safety: drug-related SAEs 4.9%; neurologic SAEs <1%; no treatment-related deaths.
- NDA submission to FDA planned for mid-2026 based on these results.

## SEC filing metadata
- accession: 0001437749-26-012751
- form_type: 8-K
- ticker: MNPR
- cik: 0001645469
- company_name: Monopar Therapeutics
- filed_at: 2026-04-20T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1645469/000143774926012751/0001437749-26-012751-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1645469/000143774926012751/mnpr20260419_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-26-012751
- JSON: https://secwatch.observer/filing/0001437749-26-012751.json
- Plain text: https://secwatch.observer/filing/0001437749-26-012751.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.